Magnetic resonance imaging findings in diagnosis and prognosis of Wilson disease
Mehri Salari1, Emad Fayyazi2, Omid Mirmosayyeb2
1 Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
2 Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences; Medical Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran
|Date of Submission||29-Apr-2016|
|Date of Decision||03-Jan-2017|
|Date of Acceptance||18-Mar-2017|
|Date of Web Publication||27-Mar-2018|
Dr. Omid Mirmosayyeb
Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. Medical Student Research Committee, Isfahan University of Medical Sciences, Isfahan
Source of Support: None, Conflict of Interest: None
Wilson disease (WD) is a rare autosomal recessive disorder characterized by excessive copper deposition in the body, principally in the liver and the brain. There is a wide spectrum of clinical presentations, but the most significant and basic symptoms of the disease can be divided into hepatic, neurologic, and psychiatric manifestations. Magnetic resonance imaging (MRI) provides more detailed anatomical information than computed tomography of the brain, especially of the structure of the basal ganglia and brain stem. In this review, we want to evaluate the correlation between MRI findings and clinical features of WD.
Keywords: Hepatocerebral degeneration, magnetic resonance imaging, Wilson disease
|How to cite this article:|
Salari M, Fayyazi E, Mirmosayyeb O. Magnetic resonance imaging findings in diagnosis and prognosis of Wilson disease. J Res Med Sci 2018;23:23
|How to cite this URL:|
Salari M, Fayyazi E, Mirmosayyeb O. Magnetic resonance imaging findings in diagnosis and prognosis of Wilson disease. J Res Med Sci [serial online] 2018 [cited 2020 Jan 27];23:23. Available from: http://www.jmsjournal.net/text.asp?2018/23/1/23/228586
| Introduction|| |
Wilson disease (WD) is a rare autosomal recessive disorder characterized by excessive copper deposition in the body, principally in the liver and the brain. The involved gene ATP7B encodes a copper-transporting P-type ATPase. More than 500 ATP7B mutations have recently been identified. Less common genetic pathways, including complete exon deletions, promoter region mutations, simultaneous presence of three pathogenic variations, and monogenic disomy have also been detected but are relatively rare. Loss of ATP7B function results in reduced hepatic biliary copper excretion reduced assimilation of copper into ceruloplasmin and the accumulation of copper in many tissues.
There is a wide spectrum of clinical presentations, but the most significant and basic symptoms of the disease can be divided into hepatic, neurologic, and psychiatric manifestations. The neurologic presentation develops in almost 40%–50% of patients and typically begins in the second or third decade. Tremor is the most common neurologic symptom occurred in about 80% patients with the neurologic manifestation. The diagnosis of WD is based on the detection of Kayser–Fleischer rings, low ceruloplasmin, raised urine and hepatic copper level, signs of liver and/or neurologic deficit, and related histologic alterations in the liver.
Magnetic resonance imaging (MRI) is the most important neuroradiological instrument for the monitoring of both diagnosis and treatment in WD. The typical MRI finding is designated as symmetric hyperintensity or mixed intensity in T2-weighted (T2W) images in the pons, midbrain, and basal ganglion. The cerebellum, corticospinal tracts, cortex, and subcortical area are also affected. Theoretically, pathognomonic MRI findings include “the faces of the giant and miniature panda” and the “trident” signs was also reported in other neurodegenerative disorders.
In this review, we want to evaluate the correlation between MRI findings and clinical features of WD.
| Methods|| |
Two of authors (OM and EF) independently searched the Medline, Central Register of Controlled Trials, and clinicaltrials.gov databases (published between January 01, 2000, and July 31, 2016) using the terms WD, MRI, and hepatolenticular degeneration. A comprehensive literature search was performed by an author with expertise in neurology and systematic review methodology. Review articles and references of all papers were assessed for potentially related studies.
The following criteria were used to include studies:
- WD was defined according to accepted international diagnostic criteria
- MRI findings in WD were calculated
- Papers were published in English.
After removing duplicate data, abstracts, and in some cases, full text of paper, were screened by two reviewers independently to assess the eligibility of the study to be included in our study. All potentially eligible studies were reviewed independently by the two trained reviewers (OM and EF). Any discrepancies following full article review were solved by a third reviewer (MS).
| Magnetic Resonance Imaging Findings of Wilson Disease|| |
WD is an inherited autosomal recessive disease of copper metabolism resulting in copper toxicity. This was first described in 1912 by Kinnier Wilson as “progressive lenticular degeneration.” Inborn defect in copper metabolism characterized by abnormal accumulation of copper in several tissues, particularly in the liver and the brain. MRI findings were used in the clinical treatment of patients with WD. Brain MRI in WD patients takes a main place for the diagnosis of these neurological forms. Structural brain MRI demonstrates extensive atrophy, and hypersignals in fluid-attenuated inversion recovery (FLAIR) and diffusion sequences in basal ganglia, cerebellar peduncles, and midbrain. Hyposignals in FLAIR sequences can be seen at a later stage of the disease after several years of treatment. In hepatic forms with portacaval shunt, nonspecific bilateral striatal hypersignals are observed on T1 sequences. Abnormalities of corticosubcortical white matter, compared with the deep nuclear structures, have received less consideration in WD. White-matter changes are observed in about 25%–40% of patients, often asymmetrical with frontal preference. MRI revealed abnormalities in the basal ganglia, cerebral white matter, midbrain, pons, and cerebellum. The paramagnetic effects of copper were found only in untreated patients. Patients with a longer duration of WD had less severe changes in signal intensity. The most commonly affected site seen on MRI was the putamen, with a distinctive lateral rim of high-signal intensity on the T2W images. Abnormalities in the remainder of the basal ganglia, namely, the ventral nuclear mass of the thalami, caudate, and globus pallidus, were found only in the presence of an abnormal putamen. The second most commonly affected site was the pons, followed by the midbrain, cortical white matter, and cerebellum. Abnormalities in signal intensity were most commonly seen on the T2W images. MRI provides more detailed anatomical information than CT of the brain, especially of the structure of the basal ganglia and brain stem. It also provides biochemical information on the distribution of heavy metal in the brain substance; MRI is clearly a useful method for assessing heavy metal storage disease. Hence, there are known signs of WD on MRI. On T2W images, the signal intensities of the basal ganglia may change. An increased signal is considered as a correlate of toxic damage and can be partly reversible. In the study of Alanen et al., MRI of the patients showed high-signal intensity areas in posterior thalamus, general atrophy, and pontine myelinolysis were present in the patients with clinical manifestations. The T2 measurement of these areas confirmed the result of image analysis. Apart from general atrophy, the changes in the patients with clinical disease were largely reversible. Published MRI studies of WD have shown a number of abnormalities, including focal atrophy, high-intensity lesions, as well as hypodense areas on T2W imaging. Attempts have formerly been made to correlate these MRI changes with clinical progression or diagnosis, with varying degrees of success. Other imaging modalities have also been used in conjunction with MRI, including positron emission tomography and single-photon emission computed tomography. Further, abnormalities may occur in the brainstem (e.g., the face of the giant panda's sign). The T2W horizontal section of the midbrain in these patients showed the “face of giant panda” appearance, which we describe for the first time and is specific for WD. Hyperintensity in the T2W image was also observed in the pontine tegmentum, medulla oblongata, and the cerebellar white matter around the dentate nucleus; the latter structures were thought to be normal. The superior colliculus, which in normal controls show the same signal intensity as cerebral white matter, showed a remarkable decrease in signal intensity in the patients with WD. In some WD patients treated with D-penicillamine with reduced dietary copper, T2W MRI showed high-intense integrities symmetrically in the bilateral lenticular nuclei and thalami in the right frontal subcortical white matter. In one study found that the basal ganglia was the most frequently affected site and always involved the putamen, with abnormality in the globus pallidus, caudate, and thalami occurring in about half of the WD patients. Hence, the MRI findings in WD patients represent the neuropathologic spectrum of spongy to cystic degeneration of gray matter nuclei; central pontine myelinolysis; and softening, gliosis, and demyelination of nerve fibers [Table 1].
|Table 1: Clinical studies on the correlation of magnetic resonance imaging findings in Wilson disease|
Click here to view
| Correlation of Magnetic Resonance Imaging Findings With Clinical Characteristics of Wilson Disease|| |
There are the ranges of abnormalities seen on cranial MRI of patients with WD, and they correlate the findings with clinical severity, duration of disease, and duration of neurologic signs and symptoms before treatment.
Regarding to dysarthria, most consistent pathological feature was globus pallidus and then thalamus, also about tremor. Chorea mostly accompanying with caudate lesions, nystagmus with lentiform lesions and thalamus, rigidity with lentiform, white matter and thalamus lesions, and dystonia with globos pallidus and putamen. In one study about a few patients with WD, T2W MRI of the midbrain in all three revealed the characteristic “face of the giant panda” sign, consisting of high signal intensity in the tegmentum except for red nucleus, preservation of signal intensity of the lateral portion of the pars reticulata of the substantia nigra, and hypointensity of the superior colliculus. There clinical manifestations in these patients with these MRI pattern were rigidity, dysarthria, and also showed tremor and dystonia. In another study brain, MRI revealed symmetrical hyperintensities on T2/T2 fluid attenuation inversion recovery images in the putamen, thalami, midbrain, pons, and subcortical white matter of both frontal lobes in one patient with decreased sleep, irrelevant speech, aggressive, and bizarre behavior. The severity of changes in signal intensity on MRI was inversely related to the duration of untreated disease and similarly related to the overall duration of disease. In contrast, no significant relationship was found between the extent of disease seen on MRI and the total duration of disease or its untreated duration. Neurologic severity was unrelated to the duration of untreated disease or to total duration of disease.
| Conclusion|| |
MRI is the most important neuroradiological instrument for the monitoring of both diagnosis and treatment in WD. MRI studies of WD have demonstrated a number of abnormalities, including focal atrophy and high-intensity lesions, as well as hypodense areas on T2W imaging. Attempts have formerly been made to correlate these MRI changes with clinical progression or diagnosis, with varying degrees of success. More clinical studies should be done to clarify the role of MRI findings in the diagnosis and prognosis of WD.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Ljubic H, Kalauz M, Telarovic S, Ferenci P, Ostojic R, Noli MC, et al.
ATP7B gene mutations in croatian patients with wilson disease. Genet Test Mol Biomarkers 2016;20:112-7.
Kelly D, Crotty G, O'Mullane J, Stapleton M, Sweeney B, O'Sullivan SS. The clinical utility of a low serum ceruloplasmin measurement in the diagnosis of wilson disease. Ir Med J 2016;109:341-3.
Ranjan A, Kalita J, Kumar S, Bhoi SK, Misra UK. A study of MRI changes in Wilson disease and its correlation with clinical features and outcome. Clin Neurol Neurosurg 2015;138:31-6.
Compston A. Progressive lenticular degeneration: A familial nervous disease associated with cirrhosis of the liver, by S. A. Kinnier Wilson, (From the National Hospital, and the Laboratory of the National Hospital, Queen Square, London) Brain 1912;34:295-509. Brain 2009;132(Pt 8):1997-2001.
van Wassenaer-van Hall HN, van den Heuvel AG, Algra A, Hoogenraad TU, Mali WP. Wilson disease: Findings at MR imaging and CT of the brain with clinical correlation. Radiology 1996;198:531-6.
King AD, Walshe JM, Kendall BE, Chinn RJ, Paley MN, Wilkinson ID, et al.
Cranial MR imaging in Wilson's disease. AJR Am J Roentgenol 1996;167:1579-84.
Trocello JM, Guichard JP, Leyendecker A, Pernon M, Chaine P, El Balkhi S, et al.
Corpus callosum abnormalities in Wilson's disease. J Neurol Neurosurg Psychiatry 2011;82:1119-21.
Sinha S, Taly AB, Ravishankar S, Prashanth LK, Venugopal KS, Arunodaya GR, et al.
Wilson's disease: Cranial MRI observations and clinical correlation. Neuroradiology 2006;48:613-21.
Hitoshi S, Iwata M, Yoshikawa K. Mid-brain pathology of Wilson's disease: MRI analysis of three cases. J Neurol Neurosurg Psychiatry 1991;54:624-6.
Sinha S, Taly AB, Prashanth LK, Ravishankar S, Arunodaya GR, Vasudev MK. Sequential MRI changes in Wilson's disease with de-coppering therapy: A study of 50 patients. Br J Radiol 2007;80:744-9.
Alanen A, Komu M, Penttinen M, Leino R. Magnetic resonance imaging and proton MR spectroscopy in Wilson's disease. Br J Radiol 1999;72:749-56.
Page RA, Davie CA, MacManus D, Miszkiel KA, Walshe JM, Miller DH, et al.
Clinical correlation of brain MRI and MRS abnormalities in patients with Wilson disease. Neurology 2004;63:638-43.
Fritzsch D, Reiss-Zimmermann M, Trampel R, Turner R, Hoffmann KT, Schäfer A. Seven-tesla magnetic resonance imaging in Wilson disease using quantitative susceptibility mapping for measurement of copper accumulation. Invest Radiol 2014;49:299-306.
George U, Varte N, Rathore S, Jain V, Goyal S. “Split thalamus”: Internal medullary involvement in Wilson's disease. Neurol India 2010;58:680.